Ladysmith Nursing Home | |
1001 E 11th St N, Ladysmith, Wisconsin 54848 | |
(715) 532-5546 | |
Name | Ladysmith Nursing Home |
---|---|
Location | 1001 E 11th St N, Ladysmith, Wisconsin |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 32 |
Occupancy Rate | 59.06% |
Medicare ID (CCN) | 525592 |
Legal Business Name | Ladysmith Nursing Home Inc |
Ownership Type | For Profit - Corporation |
NPI Number | 1184386484 |
Organization Name | SENIOR MANAGEMENT INC. |
Address | 1001 E 11th St N, Ladysmith, WI 54848 |
Phone Number | 715-532-5546 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.
In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."
The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.
Paramedics can reduce someone's chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium ("GIK") to people having a heart attack, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.
› Verified 8 days ago
NPI Number | 1285632331 |
Organization Name | LADYSMITH NURSING HOME INC |
Address | 1001 E 11th St N, Ladysmith, WI 54848 |
Phone Number | 715-532-5546 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.
In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."
The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.
Paramedics can reduce someone's chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium ("GIK") to people having a heart attack, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.
› Verified 8 days ago
NPI Number | 1770245078 |
Organization Name | SENIOR MANAGEMENT INC. |
Address | 1001 E 11th St N, Ladysmith, WI 54848 |
Phone Number | 715-532-5546 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.
In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."
The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.
Paramedics can reduce someone's chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium ("GIK") to people having a heart attack, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.
› Verified 8 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.
In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."
The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.
Paramedics can reduce someone's chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium ("GIK") to people having a heart attack, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.
› Verified 8 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 7.41 | 14.46 |
Percentage of long-stay residents who lose too much weight | 1.89 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 47.83 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 8.97 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.6 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 2.67 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.8 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.94 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 14.47 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 85.71 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.32 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 20.01 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 10.91 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 5.88 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 89.66 | 95.98 |
Percentage of short-stay residents who made improvements in function | 78.27 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 86.76 | 82.93 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.
In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."
The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.
Paramedics can reduce someone's chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium ("GIK") to people having a heart attack, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.
› Verified 8 days ago
Ladysmith Living Center, Inc Location: 1001 E 11th St N, Ladysmith, Wisconsin 54848 Phone: (715) 532-5546 |